|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
lapatinib results in decreased activity of ABCB11 protein |
CTD |
PMID:20829430 PMID:23956101 PMID:28437613 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:18829547 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
lapatinib results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:18829547 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein] |
CTD |
PMID:26643609 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation decreases activity decreases expression |
ISO |
[Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein] Lapatinib results in decreased phosphorylation of AKT1 protein lapatinib results in decreased activity of AKT1 protein lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form |
CTD |
PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 PMID:29387217 PMID:32890875 PMID:33396024 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein |
CTD |
PMID:26643609 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Lapatinib results in increased expression of BAX protein 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]] |
CTD |
PMID:29387217 PMID:32890875 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Lapatinib results in decreased expression of BCL2 protein 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]] |
CTD |
PMID:29387217 PMID:32890875 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
lapatinib results in decreased expression of BIRC5 protein |
CTD |
PMID:16091755 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA] |
CTD |
PMID:25981168 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
Lapatinib results in increased cleavage of CASP3 protein 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]] |
CTD |
PMID:29387217 PMID:32890875 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein] |
CTD |
PMID:29387217 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
lapatinib results in decreased expression of CCNA2 protein |
CTD |
PMID:25221644 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; [afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]] lapatinib results in decreased expression of CCND1 protein |
CTD |
PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] |
CTD |
PMID:15665275 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd24 |
CD24 molecule |
multiple interactions |
ISO |
[lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein |
CTD |
PMID:26643609 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
multiple interactions |
ISO |
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]] |
CTD |
PMID:26643609 PMID:33396024 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein] |
CTD |
PMID:26643609 PMID:32890875 PMID:33396024 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein] |
CTD |
PMID:26643609 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] |
CTD |
PMID:15665275 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] |
CTD |
PMID:32890875 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
[afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] lapatinib results in increased expression of CDKN1B protein |
CTD |
PMID:15665275 PMID:20701607 PMID:32890875 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Lapatinib results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Lapatinib results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO |
CYP3A4 protein results in increased metabolism of Lapatinib [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA |
CTD |
PMID:26958860 PMID:33259822 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases metabolic processing multiple interactions |
ISO |
CYP3A5 protein results in increased metabolism of lapatinib [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein |
CTD |
PMID:26958860 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases activity affects response to substance multiple interactions |
ISO |
lapatinib results in decreased activity of EGFR protein EGFR protein affects the susceptibility to lapatinib KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] |
CTD |
PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions decreases phosphorylation decreases expression decreases activity |
ISO |
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] lapatinib results in decreased phosphorylation of ERBB2 protein lapatinib results in decreased expression of ERBB2 protein lapatinib results in decreased activity of ERBB2 protein |
CTD |
PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 PMID:20549698 PMID:20701607 PMID:25221644 PMID:26643609 More...
|
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression decreases activity |
ISO |
lapatinib results in decreased expression of ERBB3 protein modified form lapatinib results in decreased activity of ERBB3 protein |
CTD |
PMID:19435893 PMID:19509167 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases activity multiple interactions |
ISO |
lapatinib results in decreased activity of ESR1 protein [lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein |
CTD |
PMID:15665275 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
ISO |
Lapatinib results in increased secretion of GPT protein |
CTD |
PMID:29655783 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]] |
CTD |
PMID:25981168 PMID:32890875 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA lapatinib metabolite results in increased expression of HMOX1 mRNA |
CTD |
PMID:26958860 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:32890875 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases response to substance multiple interactions |
ISO |
KRAS protein results in decreased susceptibility to lapatinib KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib] |
CTD |
PMID:28739874 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation decreases expression decreases activity |
ISO |
ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein] lapatinib results in decreased phosphorylation of MAPK1 protein lapatinib results in decreased expression of MAPK1 protein lapatinib results in decreased activity of MAPK1 protein |
CTD |
PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 PMID:33396024 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
multiple interactions |
ISO |
lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]] |
CTD |
PMID:28739874 |
|
NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation decreases expression decreases activity |
ISO |
ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein] lapatinib results in decreased phosphorylation of MAPK3 protein lapatinib results in decreased expression of MAPK3 protein lapatinib results in decreased activity of MAPK3 protein |
CTD |
PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 PMID:33396024 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
multiple interactions decreases expression |
ISO |
ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein] |
CTD |
PMID:25221644 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein] |
CTD |
PMID:26643609 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases activity |
ISO |
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein lapatinib metabolite results in increased activity of NFE2L2 protein |
CTD |
PMID:26958860 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA lapatinib metabolite results in increased expression of NQO1 mRNA |
CTD |
PMID:26958860 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]] |
CTD |
PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]] |
CTD |
PMID:32890875 PMID:33396024 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]] |
CTD |
PMID:32890875 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn3 |
protein tyrosine phosphatase, non-receptor type 3 |
multiple interactions |
ISO |
lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] |
CTD |
PMID:28739874 |
|
NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:32890875 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:32890875 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein] |
CTD |
PMID:26643609 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions decreases response to substance |
ISO |
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein] SNAI1 protein results in decreased susceptibility to lapatinib |
CTD |
PMID:26643609 PMID:32890875 PMID:33396024 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions |
ISO |
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]] |
CTD |
PMID:33396024 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA |
CTD |
PMID:26958860 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA lapatinib metabolite results in increased expression of SOD2 mRNA |
CTD |
PMID:26958860 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
multiple interactions |
ISO |
[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein |
CTD |
PMID:26643609 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein] |
CTD |
PMID:26643609 PMID:32890875 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:32890875 PMID:33396024 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases response to substance |
ISO |
TGFB1 protein results in decreased susceptibility to lapatinib |
CTD |
PMID:26643609 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
multiple interactions |
ISO |
Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]] |
CTD |
PMID:33396024 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
decreases activity multiple interactions |
ISO |
Lapatinib results in decreased activity of UGT1A3 protein [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid; [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid |
CTD |
PMID:31299240 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]] |
CTD |
PMID:32890875 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein] |
CTD |
PMID:26643609 PMID:32890875 PMID:33396024 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|